Fig. 2
Cumulative incidence risk of composite renal outcome (sustained ≥ 40% decline in eGFR or the development of ESKD) for patients with T2DM in different categories of baseline BMI and initial BW loss associated with SGLT2i treatment. Patients with overweight (BMI: 23.0–24.9 kg/m2), pre-obese (BMI: 25.0–29.9 kg/m2), and obese I (BMI: 30.0–34.9 kg/m2) were associated with a substantially lower cumulative risk of composite renal outcome than those with a normal body weight at baseline (BMI: 18.5–22.9 kg/m2), whereas patients with underweight (BMI < 18.5 kg/m2) at baseline was associated with a higher cumulative risk of adverse renal event than those with a normal body weight at baseline (Log-rank p < 0.0001) (A). The cumulative risk of composite renal outcome appeared to be the lowest among patients with a modest BW loss of 0.0–2.4% and 2.5–4.9%, while the cumulative risk of composite renal outcome was the highest among patients with a pronounced BW loss of ≥ 10.0% (Log-rank p < 0.0001) (B). BMI body mass index, BW body weight, eGFR estimated glomerular filtration rate, ESKD end stage kidney disease, SGLT2i sodium glucose cotransporter 2 inhibitors, T2DM type 2 diabetes mellitus